Viewing Study NCT06654050

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:13 PM
Ignite Modification Date: 2026-01-22 @ 1:08 AM
Study NCT ID: NCT06654050
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-24
First Post: 2024-10-22
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Mesothelioma View
None Malignant Mesothelioma (MM) View
None Early-stage Mesothelioma View
None Subclinical Mesothelioma View
None BRCA1-Associated Protein-1 (BAP1) Mutations View
None Early-stage BAP1-associated Malignancies View
Keywords:

Keywords

Keyword Brief Keyword Text View
None BRCA1-Associated Protein-1 (BAP1) View
None BAP1 Cancer Syndrome (BCS) View
None BAP1 Cancer Predisposition Syndrome (CPDS) View
None ring finger domains 1 (UHRF1) View
None mdm2 inhibitors (MDM2 inhibitors) View
None p53 View
None DNA methyltransferases 1 (DNMT1) View
None peripheral immune subsets View